Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChina Medical University, China

About this trial

Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Signed informed consent form and voluntary participation in this study

Histologically and/or cytologically confirmed diagnosis of cancer

Esophageal cancer

Disqualifiers

Pregnant or lactating women

Presence of contraindications to surgery

Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate

Presence of two or more concurrent primary tumors

Trial design

Treatments tested in this trial

  • Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients
  • Standard nutritional intervention was administered as a positive control to validate experimental efficacy.
  • Administration of placebo as a negative control to validate experimental efficacy

Treatment groups

1,000 Participants
are divided into 3 treatment groups